Business Wire

IENTC Telecomunicaciones Selects VectorMax Corporation to Deliver IP Live Linear with SVOD to Support Growth in Mexico

Share

IENTC Telecomunicaciones, an internet and television service provider operating in the Mexican market, today announced it is launching VectorMax’s turn-key IPTV Platform as the software to support its new television product. Serving the market for more than 10 years, IENTC Telecomunicaciones’ new service augmenting its consumer offering reflects the growing shift from broadcast television to IP delivery of live linear TV.

This marks the first commercial deployment of an all software solution enabling operators to transition from broadcast to online delivery of live linear television without having to upgrade their network architecture. The software leverages $73M of R&D from teams out of MIT, IBM Labs, Bell Labs, DARPA and MPEG related projects to deliver multicast live linear as a turn-key, fully integrated, multicast software platform for cable operators, telcos, and high-speed access providers.

“Operators need to transition and support their entertainment experiences to remain relevant and competitive,” said Peter von Schlossberg, VectorMax’s President Global Product. “Our operators are searching for solutions to deliver a live linear consumer experience side-by-side with SVOD offerings from Netflix, Hulu, Amazon, Google, etc. VectorMax developed a unique software solution that capitalizes on existing infrastructure and networks to deliver high-quality live linear broadcast & other IP services.

“Transitioning to online delivery of live linear can be daunting, but VectorMax’s software platform allowed us to quickly see our consumer offering ingested and delivered in multicast by the VectorMax software. Our own branded Streaming Media Player apps on Amazon FireTV, Roku, Android STBs, Smart TVs and iOS were live within weeks. VectorMax’s ‘show-me’ sales strategy enabled us to easily determine they were the best fit to support the growing demands of our customers,” said Carlos Arguimbau, CEO of IENTC.

VectorMax’s ability to execute technological and marketing solutions with minimal disruption to our existing operations assured us that they were an important resource to navigate new market dynamics. The end product is a win-win for both IENTC and our customers,” said Arguimbau.

IENTC’s new +TV service is bolstered by a recent study from Hub Entertainment Research. The study found that the average number of television services accessed online per viewer in the US in the past 24 months reflected a rise of over 50%. That number is expected to trend globally. IENTC is also tracking the Hub findings reflecting pay-TV subscribers who have used an operator provided set-top box to watch streaming services tend to keep using it; 58% do so to access Netflix, 61% for Amazon, and 57% for Hulu.

“These findings are a key validation of providers’ efforts to aggregate streaming services as another way to create value in the set-top box and reduce cord-cutting”, said von Schlossberg.“VectorMax deployed our Platform in December which is now being expanded to a wider area of IENTC’s footprint in Mexico. Strategically, we are positioned to help cable companies and telecoms address this shift and to market new services as easily as flicking on a switch. The VectorMax Platform is slated for a roll-out to additional customers starting Q3 2020”.

About VectorMax Corporation

VectorMax’s pioneering of technologies that increase the efficiencies in delivering IP video over large scale, fully developed, and imperfect networks, solves the evolution of live linear broadcast television to on-network online delivery. The Company holds 102 worldwide patents grounded in software-based IP transport delivery technologies.

Supported with $73 million of R&D and twelve years of intensive research and development, conducted by a development team with MIT, IBM Labs, Bell Labs, DARPA & MPEG credentials, the Company delivers a complete end to end platform comprised of multiple modules designed to work together to deliver IPTV to large scale audiences over less than optimal networks within bandwidth constrained and limited infrastructure environments. The carrier requires no other third-party component to ingest, encode, manage and deliver the immersive experience that 2020 subscribers expect. Discover more at www.vectormax.com.

About IENTC Telecomunicaciones

IENTC Telecomunicaciones is a company with more than 10 years in the telecommunications industry located in the central zone of Mexico. With high-speed internet that is offered through its’ own fiber-optic network, providing best in class service and a customer experience that guarantees business is always connected. IENTC has the most advanced technology available in the market, which enables the offering of additional services such as Mobile phone, Virtual PBX, Smart Internet, and Television services among others. Discover more at ientc.com.

Contact information

Bryen Aoyama
+1 (310) 403-2579
bryen@vectormax.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom